Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
04/2003
04/03/2003CA2453985A1 Receptors and membrane-associated proteins
04/02/2003EP1298201A1 Process for the production of cells exhibiting an islet-beta-cell-like state
04/02/2003EP1297850A1 Medicinal preparations for treating sex hormone-dependent diseases
04/02/2003EP1297838A1 Pralmorelin-containing nasal drop preparations
04/02/2003EP1297833A1 Indole carboxylic acids as thyroid receptor ligands
04/02/2003EP1297137A2 Gp286 nucleic acids and polypeptides
04/02/2003EP1297014A2 Transporters and ion channels
04/02/2003EP1297000A2 Peptides mimicking the biological activity of steroid hormones and their uses
04/02/2003EP1296976A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
04/02/2003EP1296936A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
04/02/2003EP1296681A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
04/02/2003EP1296666A2 Improved thyroid hormone formulations
04/02/2003EP1296660A1 The controlled release preparation of insulin and its method
04/02/2003EP1296646A2 Oral pharmaceutical compositions containing terbinafine
04/02/2003EP1296645A2 Methods for treating inflammation-mediated conditions of the eye
04/02/2003EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5
04/02/2003EP1263448A4 Maca and antler for augmenting testosterone levels
04/02/2003EP1114051B1 INHIBITORS OF p38
04/02/2003EP1043993B1 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
04/02/2003EP0873295B1 Dimer-selective rxr modulators and methods for their use
04/02/2003CN1407985A Heterocyclic dihydropyrimidine as potassium path inhibitor
04/02/2003CN1407898A Novel topical oestroprogestational compositions with systemic effect
04/02/2003CN1407897A DHEA composition and method
04/02/2003CN1406587A Use of activated carbon in oral medicinal preparation for hyperthyroidism
04/02/2003CN1104418C Benzoheterocyclic derivatives
04/01/2003US6541634 Process for preparing growth hormone secretagogues
04/01/2003US6541465 Orally active androgens
04/01/2003US6541463 Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
04/01/2003US6541220 Novel parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), receptors (PTH1R and PTH3R) isolated from zebrafish; vectors, host cells, recombinant methods for producing; use in identifying receptor agonists, antagonists
04/01/2003US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion
04/01/2003US6540983 A drug selected from an insulin analog, and/or amylin, a fluid propellant carrier, and a stabilizer comprising water added in addition to nascent formulation water; treating diabetes; inhalers
03/2003
03/28/2003CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003024993A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
03/27/2003WO2003024946A2 Oxamate derivatives containing a variously substituted nitrogen heterocycle
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024465A2 Use of extracts of the genus cimicifuga as organoselective medicines
03/27/2003WO2003024438A1 Composition comprising cysteamine for improving lactation in dairy animals
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002013802A3 Method of treating estrogen receptor positive carcinoma
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030059877 Human cystine knot polypeptide
03/27/2003US20030059869 Novel G protein-coupled receptor, GAVE3
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059805 Nucleotide sequences coding polyeptide for use in the treatment of growth disorders in humans
03/27/2003CA2460885A1 Composition comprising cysteamine for improving lactation in dairy animals
03/27/2003CA2460808A1 Immune response associated proteins
03/27/2003CA2459773A1 Enamel matrix protein compositions for modulating immune response
03/27/2003CA2459140A1 Protein modification and maintenance molecules
03/27/2003CA2459022A1 Neurotransmission-associated proteins
03/26/2003EP1296142A2 Calcium receptor active molecules
03/26/2003EP1295939A1 Insulin-like growth factor binding protein
03/26/2003EP1295600A2 Medicament based on gestagens for dermal application
03/26/2003EP1294882A2 B7-like molecules and uses thereof
03/26/2003EP1294873A1 Tumour suppressor and uses thereof
03/26/2003EP1294856A1 DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
03/26/2003EP1294739A1 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity
03/26/2003EP1294724A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
03/26/2003EP1294716A1 Lactam inhibitors of factor xa and method
03/26/2003EP1294699A2 Modulators of tnf- alpha signalling
03/26/2003EP1294391A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
03/26/2003EP1294389A1 THERAPEUTICAL USE OF i SOPHORA FLAVESCENS /i OR i SOPHORA SUBPROSTRATA /i EXTRACTS
03/26/2003EP1294388A1 EXTRACTS FROM i SOPHORA /i SPECIES, METHOD FOR PRODUCING THE SAME AND THEIR USE
03/26/2003EP1294384A2 Use of lanthanum compounds for the treatment of bone diseases
03/26/2003EP1294227A2 Transgenic mice containing nuclear hormone receptor gene disruptions
03/26/2003EP1146873A4 Anti-androgens and methods for treating disease
03/26/2003EP1140960A4 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
03/26/2003CN1404829A Double inhibitor synthesized by wax ester and cholesterol ester for inbibiting generation of sebum
03/26/2003CN1103590C Use of thiazolidinediones to prevent or delay on set of NIDDM
03/25/2003US6538019 Produce emulsions containing a material that are insoluble or that have low solubility with respect to water and oil in a high concentration, so as to obtain emulsions which can be preserved for a long period of time. More specifically,
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6537998 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
03/25/2003US6537578 Once-a-day controlled release sulfonylurea formulation
03/25/2003US6537559 Staphylococcus aureus antigen-containing whole cell vaccine
03/20/2003WO2003023014A2 Human ion channels
03/20/2003WO2003022864A1 17alpha-hydroxy-14beta-steroids with hormonal effect
03/20/2003WO2003022835A1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
03/20/2003WO2003022303A2 Use of hcg and lh in controlled ovarian hyperstimulation
03/20/2003WO2003022297A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue
03/20/2003WO2003022292A1 Oral pharmaceutical formulation containing active carbon and use of the same
03/20/2003WO2003022277A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
03/20/2003WO2003022271A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease
03/20/2003WO2003022259A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003WO2003022242A1 Preparation of sustained release pharmaceutical composition
03/20/2003WO2003002175A3 Enhanced systemic absorption of intradermally delivered substances
03/20/2003WO2002098363A3 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002091993A3 Estrogen receptor modulators
03/20/2003WO2002074045A3 Production of pancreatic islet cells and delivery of insulin
03/20/2003WO2002072602A3 Somatostatin antagonists
03/20/2003WO2002066040A8 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
03/20/2003US20030055261 Compounds with growth hormone releasing properties
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
1 ... 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 ... 290